We’re excited to share a major development that reinforces the urgency of investigating monoclonal antibodies for Long COVID.
This week, Invivyd announced that Dr. Akiko Iwasaki, Professor of Immunobiology at Yale School of Medicine and one of the world’s leading Long COVID researchers, has joined the SPEAR (Spike Protein Elimination and Recovery) Study Group.
The group is focused on the role of persistent spike protein — as well as live replicating virus or viral reservoirs — in ongoing symptoms of Long COVID and Post-Vaccine Syndrome (PVS). Emerging evidence continues to suggest that viral persistence plays a central role in the disease’s mechanisms.
Dr. Iwasaki, who leads the Yale LISTEN and Mount Sinai-Yale Long COVID studies, brings deep expertise in viral persistence and immune dysregulation. Her involvement marks a major step forward in legitimizing this path of inquiry.
The SPEAR group will help guide clinical trials evaluating the safety and exploratory efficacy of monoclonal antibodies — including PEMGARDA® (Pemivibart) and next-generation candidate VYD2311 — in patients with Long COVID and PVS.
This represents a critical shift. While PEMGARDA is not yet authorized for Long COVID treatment, multiple case reports have shown improvement in symptoms following its use. The move toward formal trials is long overdue — and Canada must not be left behind.
Read the full press release:
We’ve now reached 923 signatures. Let’s keep building momentum to bring these therapies — and hope — to Canadians.
Share the petition:
https://www.change.org/MAbsForCanadaNOW
Thank you to everyone who continues to stand with us in calling for action, research, and hope.
In solidarity,
Rowan
#LongCOVIDTrialsNOW
#ProtectImmunocompromised
#MAbsForCanadaNOW
#COVID19IsNotOver